PARSIPPANY, N.J.--(BUSINESS WIRE)--Ferring Pharmaceuticals today announced the final 60-month follow-up data from the Phase 3 study of ADSTILADRIN ® (nadofaragene firadenovec-vncg) were presented at ...
Disease-free survival rate of 58% at 12 months (primary endpoint) and 52% at 24 months Cystectomy avoidance rate of 82% at 36 months—unmatched by any product in the field to date Disease-specific ...
WASHINGTON -- The gene therapy nadofaragene firadenovec (Adstiladrin) continued to demonstrate clinical activity in patients with high-risk bladder cancer, researchers reported. The long-term ...
The “Get Moving Trial”: A phase I/II RCT of home-based (P)rehabilitation ((P)REHAB) with ExerciseRx in muscle-invasive bladder cancer (MIBC)—Study protocol for a randomized controlled trial. New phase ...
CULVER CITY, Calif.--(BUSINESS WIRE)-- ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, today announced treatment with ANKTIVA® (nogapendekin alfa inbakicept-pmln) plus Bacillus ...
rBCG offers an alternative to TICE® BCG amid U.S. shortages, impacting bladder cancer treatment availability. FDA's Expanded Access Program allows investigational rBCG use when no satisfactory ...
Intravesical bacillus Calmette-Guérin (BCG) with and without isoniazid (INH) is associated with outcomes superior to those intravesical epirubicin in patients with intermediate- and high-risk Ta and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results